Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide.
- Author:
Jungsil RO
1
;
Fiona Tsui Fen CHENG
;
Virote SRIURANPONG
;
Antonio VILLALON
;
B K SMRUTI
;
Janice TSANG
;
Yoon Sim YAP
Author Information
- Publication Type:Review
- Keywords: Asians; Breast neoplasms; Chemotherapy; Eribulin mesylate
- MeSH: Asian Continental Ancestry Group; Breast Neoplasms*; Breast*; Drug Therapy; Humans
- From:Journal of Breast Cancer 2016;19(1):8-17
- CountryRepublic of Korea
- Language:English
- Abstract: Eribulin, an antimicrotubule chemotherapeutic agent, is approved for the treatment of pretreated metastatic breast cancer (mBC) based on the positive outcomes of phase II and phase III clinical trials, which enrolled mainly Western patients. Eribulin has recently been approved in an increasing number of Asian countries; however, there is limited clinical experience in using the drug in certain countries. Therefore, we established an Asian working group to provide practical guidance for eribulin use based on our clinical experience. This paper summarizes the key clinical trials, and the management recommendations for the reported adverse events (AEs) of eribulin in mBC treatment, with an emphasis on those that are relevant to Asian patients, followed by further elaboration of our eribulin clinical experience. It is anticipated that this clinical practice guide will improve the management of AEs resulting from eribulin treatment, which will ensure that patients receive the maximum treatment benefit.
